IL91662A - Pharmaceutical preparations containing promomycin and urea for the treatment of leishmaniasis - Google Patents

Pharmaceutical preparations containing promomycin and urea for the treatment of leishmaniasis

Info

Publication number: IL91662A
Authority: IL; Israel
Prior art keywords: paromomycin; urea; composition; ester; treatment
Prior art date: 1988-09-20

Application number

IL9166289A

Other languages

English (en)

Hebrew (he)

Original Assignee

Neal Ralph Arthur

Murphy Anthony Gabriel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-20

Filing date

1989-09-18

Publication date

1994-05-30

1989-09-18 Application filed by Neal Ralph Arthur, Murphy Anthony Gabriel filed Critical Neal Ralph Arthur

1994-05-30 Publication of IL91662A publication Critical patent/IL91662A/en

Links

XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims description 28
239000004202 carbamide Substances 0.000 title claims description 28
238000011282 treatment Methods 0.000 title claims description 22
208000004554 Leishmaniasis Diseases 0.000 title description 10
239000008194 pharmaceutical composition Substances 0.000 title description 3
UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 60
239000000203 mixture Substances 0.000 claims description 59
229960001914 paromomycin Drugs 0.000 claims description 59
UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 45
231100000252 nontoxic Toxicity 0.000 claims description 20
230000003000 nontoxic effect Effects 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 19
150000002148 esters Chemical class 0.000 claims description 16
206010011668 Cutaneous leishmaniasis Diseases 0.000 claims description 14
230000000699 topical effect Effects 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 9
239000006071 cream Substances 0.000 claims description 8
239000012188 paraffin wax Substances 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
239000000843 powder Substances 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
230000000069 prophylactic effect Effects 0.000 claims description 5
238000000034 method Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000003883 ointment base Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
230000003902 lesion Effects 0.000 description 26
239000002674 ointment Substances 0.000 description 17
210000002268 wool Anatomy 0.000 description 10
150000003856 quaternary ammonium compounds Chemical class 0.000 description 8
238000011725 BALB/c mouse Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
238000009472 formulation Methods 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 5
230000000694 effects Effects 0.000 description 5
229960002285 methylbenzethonium chloride Drugs 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000222722 Leishmania <genus> Species 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
229960001760 dimethyl sulfoxide Drugs 0.000 description 3
238000012360 testing method Methods 0.000 description 3
241000215452 Lotus corniculatus Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
241000191796 Calyptosphaeria tropica Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
241000222697 Leishmania infantum Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010047505 Visceral leishmaniasis Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000009429 distress Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
239000003973 paint Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037390 scarring Effects 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL9166289A 1988-09-20 1989-09-18 Pharmaceutical preparations containing promomycin and urea for the treatment of leishmaniasis IL91662A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB888822052A GB8822052D0 (en)	1988-09-20	1988-09-20	Compositions for treatment of leishmaniasis

Publications (1)

Publication Number	Publication Date
IL91662A true IL91662A (en)	1994-05-30

Family

ID=10643913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9166289A IL91662A (en)	1988-09-20	1989-09-18	Pharmaceutical preparations containing promomycin and urea for the treatment of leishmaniasis

Country Status (13)

Country	Link
EP (1)	EP0435915B1 (fr)
JP (1)	JPH04502452A (fr)
KR (1)	KR0150641B1 (fr)
DZ (1)	DZ1358A1 (fr)
GB (1)	GB8822052D0 (fr)
HU (1)	HU213111B (fr)
IL (1)	IL91662A (fr)
MA (1)	MA21630A1 (fr)
MX (1)	MX17601A (fr)
MY (1)	MY106605A (fr)
OA (1)	OA09641A (fr)
TN (1)	TNSN89102A1 (fr)
WO (1)	WO1990003174A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3057226B2 (ja) *	1997-10-09	2000-06-26	琉球大学長	グルコピラノース誘導体を有効成分とするリーシュマニア症治療剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2117237B (en)	1982-03-29	1985-07-24	Orvet Bv	Paromomycin compositions for topical treatment of cutaneous leishmaniasis

1988
- 1988-09-20 GB GB888822052A patent/GB8822052D0/en active Pending
1989
- 1989-09-18 DZ DZ890045A patent/DZ1358A1/fr active
- 1989-09-18 IL IL9166289A patent/IL91662A/en not_active IP Right Cessation
- 1989-09-19 HU HU895550A patent/HU213111B/hu unknown
- 1989-09-19 WO PCT/GB1989/001096 patent/WO1990003174A1/fr not_active Ceased
- 1989-09-19 MY MYPI89001277A patent/MY106605A/en unknown
- 1989-09-19 KR KR1019900701031A patent/KR0150641B1/ko not_active Expired - Lifetime
- 1989-09-19 EP EP89910641A patent/EP0435915B1/fr not_active Expired - Lifetime
- 1989-09-19 MA MA21884A patent/MA21630A1/fr unknown
- 1989-09-19 MX MX1760189A patent/MX17601A/es unknown
- 1989-09-19 JP JP1510004A patent/JPH04502452A/ja active Pending
- 1989-09-20 TN TNTNSN89102A patent/TNSN89102A1/fr unknown
1991
- 1991-03-20 OA OA59976A patent/OA09641A/en unknown

Also Published As

Publication number	Publication date
EP0435915B1 (fr)	1993-05-26
JPH04502452A (ja)	1992-05-07
MA21630A1 (fr)	1990-04-01
TNSN89102A1 (fr)	1991-02-04
GB8822052D0 (en)	1988-10-19
OA09641A (en)	1993-04-30
KR900701281A (ko)	1990-12-01
WO1990003174A1 (fr)	1990-04-05
MY106605A (en)	1995-06-30
HU895550D0 (en)	1991-12-30
EP0435915A1 (fr)	1991-07-10
HUT71695A (en)	1996-01-29
HU213111B (en)	1997-02-28
KR0150641B1 (ko)	1998-10-15
DZ1358A1 (fr)	2004-09-13
MX17601A (es)	1993-09-01

Legal Events

Date	Code	Title
2000-01-31	KB	Patent renewed
2003-11-23	KB	Patent renewed
2007-10-31	KB	Patent renewed
2010-05-31	EXP	Patent expired

Publication	Publication Date	Title
JP3706792B2 (ja)	2005-10-19	局所用亜鉛組成物および使用方法
US4335115A (en)	1982-06-15	Anti-acne composition
US4323582A (en)	1982-04-06	Method of treating animals and humans for internal and external parasites
EP0098743B1 (fr)	1988-09-28	Dérivés de phényl-alpha-acyloxyacétamides et leur utilisation thérapeutique
CA2528360C (fr)	2013-01-29	Composition anesthesique pour administration topique comprenant de la lidocaine, de la prilocaine, et de la tetracaine
WO2008021847A2 (fr)	2008-02-21	Formulation topique de composition de vésicules multilamellaires pour une absorption percutanée d'agent actif du point de vue pharmaceutique
WO2010039654A2 (fr)	2010-04-08	Traitement topique d'une infection de la peau
HUP0302038A2 (hu)	2003-09-29	Biguanidszármazékok alkalmazása hegesedést elżsegítż gyógyszerek elżállítására
JPH10502355A (ja)	1998-03-03	Ｎ−アセチル−ｌ−システインを含んだ局所組成物
JPS6272611A (ja)	1987-04-03	皮膚外用剤
CA1090253A (fr)	1980-11-25	Produit pour le traitement de l'acne
JPH08175986A (ja)	1996-07-09	経皮活性を示す５−アミノレブリン酸含有薬学組成物
CA1250236A (fr)	1989-02-21	Compositions antibiotiques topiques sous forme de gel
JPH06263644A (ja)	1994-09-20	リチウム治療剤
US3809749A (en)	1974-05-07	Topical pharmaceutical composition and method employing sap from the tree croton lechleri
US5128375A (en)	1992-07-07	Keloid treating agent
EP0435915B1 (fr)	1993-05-26	Compositions de traitement de la leishmaniose
EP0001871B1 (fr)	1981-07-29	Un composé d'érythromycine, un procédé de préparation de ce composé et composition contenant ce composé, utile pour le traitement de l'acné
HU193845B (en)	1987-12-28	Process for preparing synergic pharmaceutical preparations comprising flupyrthine and 4-acetamido-phenol
JPH03120230A (ja)	1991-05-22	薬効成分の経皮吸収促進剤及び経皮吸収型製剤
US6469070B1 (en)	2002-10-22	Topical medicament comprising phenolic biocide and choline
JP2705177B2 (ja)	1998-01-26	皮膚潰瘍治療剤
KR950701216A (ko)	1995-03-23	레마세미드의 파킨슨병 치료 용도(use of remacemide for the treatment of parkinson's disease)
DE68906794T2 (de)	1993-09-02	Zubereitungen zur behandlung von leishmaniasis.
HU208251B (en)	1993-09-28	Process for producing pharmaceutical compositions for reducing vasodilatation of veins